~~<i id='83ECECD77D'><strike id='83ECECD77D'><tt id='83ECECD77D'><pre id='83ECECD77D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

fashion

author：fashion 2025-09-28 15:21:12 - browse：53

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

explore

focus

knowledge

hotspot

entertainment

Sen.BernieSanders(I-Vt.)raiseshishandataThursdayhearingonCapitolHillinWashingtontoexaminethecostofpr

WSS

AMAs digital advisors table RPM coding reform proposal, again

Why don't Americans have at

Study finds gene variants tied to breast cancer risk in Black women

AMAs digital advisors table RPM coding reform proposal, again

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

As a primary care physician, here's how I hope to partner with AI

Wikipedia

fashion

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Bernie Sanders gets little from pharma CEOs on drug prices

Wildfire smoke exposes gaps in outdoor worker protections

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Dobbs anniversary: the lost opportunity of abortion as health care

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Supreme Court strikes down use of affirmative action

Long Covid research funding gets a major boost from NIH

As demand for Covid shots wanes, Moderna seeks its next success

Cue Health, Covid

focus

Listen: More tumult at BIO & coercive care for sickle cell patients

H5N1 bird flu outbreak: Second human case reported, in Michigan

Reports of telehealth's death have been greatly exaggerated

Listen: A conversation with researcher Kevin Esvelt on biosecurity

H5N1 bird flu outbreak: Second human case reported, in Michigan

Why Eli Lilly’s earnings didn’t quite live up to the hype

focus

knowledge

hotspot

entertainment